Treatment of systemic lupus erythematosus: 2013 update

Bulletin of the Hospital for Joint Diseases

Volumn 71, Issue 3, 2013, Pages 208-213

  Michael Belmont, H ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; BELIMUMAB; ECULIZUMAB; IMMUNOGLOBULIN; RITUXIMAB; TOCILIZUMAB;

ANTIBODY PRODUCTION; ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; GENERAL CONDITION IMPROVEMENT; HUMAN; INCIDENCE; INFLAMMATION; NEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN LUPUS ERYTHEMATOSUS; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIMALARIALS; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL PRODUCTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; TREATMENT OUTCOME;

EID: 84886535850     PISSN: 23284633     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Merrill JT. Treatment of systemic lupus erythematosus: a 2012 update. Bull NYU Hosp Jt Dis. 2012;70(3):172-6.
2. Akhavan PS, Su J, Lou W, et al. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol. 2013 Jun;40(6):831-41.
3. Hofmann S, Leandro M, Morris S, Isenberg D. Effects of rituximab-based B-cell depletion therapy on skin manifestation of lupus. Lupus. 2013;22(9):932-939.
4. Privette ED, Werth VP. Update on pathogenesis and treatment of CLE. Curr Opin Rheumatol. 2013 Sep; (5):584-90.
5. Artifoni M, Puéchal X. How to treat refractory arthritis in lupus? Joint Bone Spine. 2012 Jul;79(4):347-50.
6. Mok C, To C, Yu K, Ho L. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12 month prospective study. Lupus. 2013 Aug 30. [Epub ahead of print]
7. Cortes-Hernandez J, Torres- Salido MT, Medrano AS, et al. Long- term outcomes- mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant. 2010 Dec;25(12):3939-48.
8. Hogan J, Appel GB. Update on the treatment of lupus nephritis: Curr Opin Nephrol Hypertens. 2013 Mar;22(2):224-30.
9. Gunnarssoon I, Jonsdottr T. Rituximab treatment in lupus nephritis-where do we stand? Lupus. 2013;22(4):381-9.
10. Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012 Nov;64(11):3660-5.
11. Condon MB, Ashby D, Pepper RJ, et al. Prospective observa tional single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013 Aug;72(8):1280-6.
12. Karra VS. The mechanism of action of the drug “Acthar” for systemic lupus erythematosus (SLE). Available at: pharmaceuticalintelligence.com/2012/07/08/the-mechanism-ofaction-of-the-drug-acthar-for-systemic-lupus-erythematosussle/Accessed September 16, 2013
13. Bomback AS, Tumlin JA, Baranski J, et al. Treatment of nephrotic syndrome with andrenocorticotropic hormone (ACTH) gel, Drug Des Devel Ther. 2011 Mar 14;5:147-53.
14. Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Jul;64(7):2328-37.
15. Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predicators of response. Ann Rheum Dis. 2012 Aug;71(8):1343-9.
16. Dooley MA, Houssiau F, Aranow C, et al. Bliss-52 Study Group; Bliss-76 Study Group. Effect of Belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus. 2013 Jan;22(1):63-72.
17. Artinger M, Smolen JS. Therapeutic blockade of TNF in patients with SLE – promising or crazy? Autoimmun Rev. 2012 Mar;11(5):321-5.
18. Ding HJ, Gordon C. New biologic therapy for systemic lupus erythematosus. Curr Opin Pharmacol. 2013 Jun;13(3):405-12.
19. Shirota Y, Yarboro C, Ilei GG. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis. 2013 Jan:72(1);118-28.
20. Kamata Y, Minota S. Successful treatment of massive intractable pericardial effusion in a patient with systemic lupus erythematosus with tocilizumab. BMJ Case Rep. 2012 Dec 21;2012. pii: bcr2012007834. doi: 10.1136/bcr-2012-007834.
21. Alten R, Maleitzke T. Tociluzmab: a novel humanized antiinterleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic inflammatory rheumatic diseases. Ann Med. 2013 Jun;45(4):357-63.
22. Garcia-Hernandez FJ, Gonzalez-Leon R, Castillo-Palma MJ, et al. Tocilizumab for treating refractory haemolytic anaemia in a patient with systemic lupus erythematosus. Rheumatology (Oxford). 2012 Oct;51(10):1918-9.
23. Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007 Jul;56(7):2382-91.
24. Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks: A decision analysis. Arch Intern Med. 2000 Jul 10;160(13):2042-8.
25. Bertero MT. Primary prevention in antiphospholipid antibody carriers. Lupus. 2012 Jun;21(7):751-4.
26. Bucciarelli S, Espinosa G, Cervera R, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in series of 250 patients. Rheum. Arthritis. 2006 Aug;54(8):2568-76.
27. Berman H, Rodríguez-Pintó I, Cervera R, et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013 Sep;12(11)1085-90.
28. Erkan D, Vega J, Ramon G, et al. A pilot open label phase II trial of rituximab for non-criteria manifestation of antiphospholipid syndrome. Arthritis Rheum. 2013 Feb;65(2):464-71.
29. Bakshi J. Stevens R. Rituximab therapy for recurrent thromboembolic disease in antiphospholipid syndrome. Lupus. 2013 Jul;22(8):865-7.
30. McLeod BC. Therapeutic apheresis: use of human serum albumin, fresh frozen plasma and cryosupernatant plasma in therapeutic plasma exchange. Best Pract Res Clin Haematol. 2006;19(1):157-67.
31. Shapira I, Andrade D, Allen SL, Salmon JE. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 2012 Aug;64(8):2719-23.
32. Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med. 2010 May 6;362(18):1744-5.